Autoimmune giant cell myocarditis - Clinical characteristics, experimental models and future treatments

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 10, 2011, Pages 1163-1172

  Suzuki, Jun Ichi ^a   Ogawa, Masahito ^a   Watanabe, Ryo ^b   Morishita, Ryuichi ^c   Hirata, Yasunobu ^a   Nagai, Ryozo ^a   Isobe, Mitsuaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

autoimmune disease; cytokine; inflammation; myocarditis

Indexed keywords

AZATHIOPRINE; CATECHIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; FLUINDOSTATIN; I KAPPA B; INTERLEUKIN 17; METHYLPREDNISOLONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; GIANT CELL; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; MYOCARDITIS; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; GIANT CELLS; HUMANS; MYOCARDITIS; PROGNOSIS; RATS; STEM CELL TRANSPLANTATION;

EID: 80052897279     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.601294     Document Type: Review

References (50)

1. Cooper LT. Myocarditis. N Engl J Med 2009;360:1526-38
2. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274-88
3. Kodama M, Oda H, Okabe M, et al. Early and long-term mortality of the clinical subtypes of myocarditis. Jpn Circ J 2001;65:961-4
4. Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003;41:322-9
5. Davies MJ, Pomerance A, Teare RD. Idiopathic giant cell myocarditis - a distinctive clinico-pathological entity. Br Heart J 1975;37:192-5
6. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336:1860-6 (Pubitemid 27263973)
7. Kilgallen CM, Jackson E, Bankoff M, et al. A case of giant cell myocarditis and malignant thymoma: a postmortem diagnosis by needle biopsy. Clin Cardiol 1998;21:48-51 (Pubitemid 28099337)
8. Daniels PR, Berry GJ, Tazelaar HD, et al. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 2000;9:287-91
9. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-63 (Pubitemid 36241044)
10. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-2002
11. Aziz KU, Patel N, Sadullah T, et al. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010;20:509-15
12. Allanore Y, Vignaux O, Arnaud L, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249-52 (Pubitemid 43132003)
13. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75
14. Cooper LT Jr, Hare JM, Tazelaar HD, et al. Giant Cell Myocarditis Treatment Trial Investigators: usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535-9
15. Menghini VV, Savcenko V, Olson LJ, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999;74:1221-6
16. Kodama M, Matsumoto Y, Fujiwara M, et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62 (Pubitemid 20368038)
17. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 1991;147:2141-7
18. Liao L, Sindhwani R, Rojkind M, et al. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med 1995;181:1123-31
19. Afanasyeva M, Wang Y, Kaya Z, et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 2001;104:3145-51 (Pubitemid 34014072)
20. Afanasyeva M, Wang Y, Kaya Z, et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001;159:193-203 (Pubitemid 33704204)
21. Cihakova D, Barin JG, Afanasyeva M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008;172:1195-208 (Pubitemid 351671534)
22. Kaya Z, Dohmen KM, Wang Y, et al. Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 2002;168:1552-6 (Pubitemid 34135748)
23. Eriksson U, Kurrer MO, Sonderegger I, et al. Activation of dendritic cells through the role of cardiac troponins and autoimmunity in the pathogenesis of myocarditis and heart failure 87 interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 2003;197:323-31
24. Eriksson U, Kurrer MO, Schmitz N, et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 2003;107:320-5 (Pubitemid 36135231)
25. Rangachari M, Mauermann N, Marty RR, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006;203:2009-19 (Pubitemid 44188474)
26. Fairweather D, Kaya Z, Shellam GR, et al. From infection to autoimmunity. J Autoimmun 2001;16:175-86 (Pubitemid 32566105)
27. Kaya Z, Afanasyeva M, Wang Y, et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2001;2:739-45 (Pubitemid 32747164)
28. Hanawa H, Kodama M, Zhang S, et al. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol 1992;62:321-6
29. Zhang S, Kodama M, Hanawa H, et al. Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-60 (Pubitemid 23106205)
30. Suzuki J, Ogawa M, Futamatsu H, et al. A Cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006;40:688-95
31. Wakizono-Azuma R, Suzuki J, Ogawa M, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004;64:412-20 (Pubitemid 39505420)
32. Hishikari K, Watanabe R, Ogawa M, et al. Early treatment with clarithromycin attenuates ratautoimmune myocarditis via inhibition of matrix metalloproteinase activity. Heart 2010;96:523-7
33. Suzuki J, Ogawa M, Futamatsu H, et al. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation, fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007;9:152-9 (Pubitemid 46402883)
34. Futamatsu H, Suzuki J, Koga N, et al. A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation. J Mol Cell Cardiol 2006;40:853-61 (Pubitemid 43817046)
35. Suzuki J, Ogawa M, Muto S, et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008;12:783-94 (Pubitemid 352003320)
36. Suzuki J, Ogawa M, Muto S, et al. A specific inhibitor of plasminogen activator inhibitor-1 suppresses ratautoimmune myocarditis. Expert Opin Ther Targets 2008;12:1313-20
37. Ngoc PB, Suzuki J, Ogawa M, et al. The anti-inflammatory mechanism of prostaglandin E2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 2011;57:365-72
38. Hanawa H, Kodama M, Inomata T, et al. Anti-alphabeta T cell receptor antibody prevents the progression of experimental autoimmune myocarditis. Clin Exp Immunol 1994;96:470-5
39. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003;59:95-104 (Pubitemid 36776376)
40. Haga T, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway. J Mol Cell Cardiol 2009;46:719-27
41. Yokoseki O, Suzuki J, Kitabayashi H, et al. Cis element decoy against neculear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906 (Pubitemid 34627895)
42. Futamatsu H, Suzuki J Mizuno S, et al. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res 2005;96:823-30 (Pubitemid 40604965)
43. Okada H, Suzuki J, Futamatsu H, et al. Attenuation of autoimmune myocarditis in rats by mesenchymal stem cell transplantation through enhanced expression of hepatocyte growth factor. Int Heart J 2007;48:649-61 (Pubitemid 350200187)
44. Chang H, Hanawa H, Yoshida T, et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer. Circ J 2008;72:813-19 (Pubitemid 351716688)
45. Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010;185:1375-8
46. Suzuki J, Isobe M, Morishita R, et al. Effects of tea catechins on inflammation-related cardiovascular disease. Curr Immnol Rev 2009;5:167-74
47. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255-65 (Pubitemid 44394897)
48. Suzuki J, Ogawa M, Muto S, et al. Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases. Expert Opin Investig Drugs 2011;20:255-64
49. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71
50. Suzuki J, Isobe M, Morishita R, et al. Nucleic acid drugs for prevention of cardiac rejection. J Biomed Biotech 2009;published online 11 October 2009; doi:10.1155/2009/916514